DOV Pharmaceutical

DOV Pharmaceutical, a biotechnology company, focuses on therapies primarily for central nervous system conditions. The firm's lead drug candidate, Indiplon, is said to treat insomnia. Indiplon targets the same subset of neurotransmitter receptors affected by Valium and Xanax, but with more specificity to avoid the side effects associated with those drugs. DOV Pharmaceutical, Neurocrine Biosciences, and Pfizer are working on the candidate. Other candidates in DOV's pipeline target depression and angina, pain, anxiety, high blood pressure, and other disorders.